Targeted delivery of anti-inflammatory agents to tumors.
Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
Coimbra
Maria
M
Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Kuijpers
Sylvia A
SA
van Seters
Sebastiaan P
SP
Storm
Gert
G
Schiffelers
Raymond M
RM
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators